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Data resource basics
Information about pandemic dynamics is crucial to under-
stand the potential impacts on populations, design mitiga-
tion strategies and evaluate the efficacy of their
implementation. Centralization, standardization and har-
monization of data are critical to enable comparisons of
the demographic impact of COVID-19 which take into ac-
count differences in the age and sex compositions of con-
firmed infections and deaths. The international data
landscape must keep pace with the global march of the
pandemic, and researchers must work to triangulate the
available data to create comparable measures to monitor
and predict its demographic impacts.
COVerAGE-DB aims to provide global coverage of key
demographic aspects of the COVID-19 pandemic as it
unfolds in an up-to-date, transparent and open-access for-
mat. COVerAGE-DB offers data with standardized count
measures by sex and harmonized age groups, which is a
necessary but not sufficient condition to allow compari-
sons between populations at national and subnational
scales.
The database is currently under expansion through both
the increase in coverage of national and subnational popu-
lations and the inclusion of more recent periods as the pan-
demic continues. At the time of writing, the database
contains daily counts of COVID-19 cases, deaths and tests
performed, by age and sex, for 108 national and 371 sub-
national populations around the world, depending on the
available data for each source. The date range available for
each country or subpopulation varies. In several country
series, the database includes the earliest confirmed cases in
January 2020. For most populations, the database includes
daily time series, beginning from an initial starting date
when the data were first released or collected by our team.
Figure 1 displays a map of countries included in the data-
base, indicating at least one subnational population from
13 countries. A detailed overview of data availability is
given in a searchable table: [https://bit.ly/3kVDrLD].
Data collected
Official counts of COVID-19 cases, deaths, and tests are
extracted from reports published by official governmental
institutions, such as health ministries and statistical offices.
Depending on the source, data are collected in a variety of
formats, including machine-readable files, pdf tables, html
tables, interactive dashboards, press releases, official
announcements via Twitter, and in a few instances, from
digitized graphics. A full list of data sources is available in
a dashboard view [https://bit.ly/2Qg1MxL].
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Generally, COVID-19 cases, deaths and tests in age
groups are reported as counts, but some sources report
data in other metrics (fractions, percentages, ratios) or as
summary indicators such as case fatality ratios (CFRs) by
age. Reported age intervals vary by source, ranging from
single ages to 30-year or greater age bands, and sometimes
reported age intervals change over time within sources.
Usually data are reported as cross-sectional snapshots of
cumulative counts, but some sources give full time series of
new cases or deaths, in which case we cumulate counts
over time. We also collect standard metadata on each of
the sources to capture various characteristics of the col-
lected data, such as the primary collection channels, defini-
tions used and notes on major disruptions or events. An
overview of key fields from these metadata is shared as a
spreadsheet [https://bit.ly/2FAmKFn].
Data production
All source data are entered into standard spreadsheet tem-
plates hosted in a central folder on Google Drive. Data en-
try into the templates is either manual or automatic,
depending on the source.
R programs collect data from the source templates and
compile the merged input database. The merged input file
is then subject to a series of automatic validity checks.
Initial checks are carried out by the individual responsible
for data collection and entry, using an interactive applica-
tion [https://mpidr.shinyapps.io/cleaning_tracker/]. Data
are then harmonized to standard metrics (counts), meas-
ures (cases, deaths, tests) and age bands (5- and 10-year
age intervals). Harmonization procedures include rescaling
to ensure coherence between age distributions and reported
total counts. Age group harmonization is done using the
penalized composite link model for ungrouping1 which
was designed for splitting histograms of count data.
Output data also include a file containing selected diagnos-
tics of data quality, such as completeness of age reporting,
for each source and date.
The complete details on all steps of production are
available in the COVerAGE-DB Method Protocol, which
is publicly available on the web.2 A table listing which
adjustments are applied to each population is available on
the project website [https://bit.ly/2E61BSV]. The merged
input database, the harmonized output and the data qual-
ity files are uploaded daily as zipped csv files to an Open
Science Framework repository (OSF) [https://osf.io/mpwjq/].
A GitHub repository [https://bit.ly/2YbtPCJ], which is
linked to OSF, contains all R scripts used in the complete
production pipeline, including compilation, diagnostics and
harmonization.
Data resource use
Since collection efforts began for COVerAGE-DB in late
March 2020, we are aware of 15 studies using the data,
many of which provide R code online and are fully repro-
ducible. Broadly, these studies aim to measure the
influence of demographic factors on mortality from
COVID-19,3,4 assess the pandemic impact on health and
mortality within5,6 and across populations,7–12 analyse
COVID-19 data availability and quality,13 propose meth-
odological innovations that allow comparisons of CFRs14
and the development of indirect methods to estimate infec-
tions in the population.15,16 The database is also used to
monitor COVID-19 impacts in particular age ranges. For
instance, UNICEF has used the database for monitoring
the burden of the pandemic on children around the
world17 and the UN Department of Economic and Social
Affairs has used it similarly to focus on older age groups.18
As an example of the analyses that COVerAGE-DB ena-
bles, Figure 2 displays changes in the relation between age-
specific deaths and cases rates in Colombia, inspired by
Figure 1 of Dudel et al.14 We divide both cases and deaths
in each age band by the respective population sizes.
Diagonal lines indicate age-specific CFRs. The graph illus-
trates a sharp increase in CFR over age for each sex, and
displays considerable sex differences. For instance, men
aged 60–69 in Colombia have almost the same CFR (ap-
proximately 12% risk of death after COVID-19 disease di-
agnosis) as women aged 70–79.
We repeat this exercise to compare Colombia with
Mexico (see Figure 3), where standardizing by population
size is more justified. CFRs and death rates are much
higher in Mexico than in Colombia in each age band—
around 2-fold—except for ages 80þ, which show a sub-
stantial reduction in the CFR difference, and much higher
death rates for Colombia.
This comparison between Colombia and Mexico allows
us to illustrate several issues in data quality to be consid-
ered when comparing COVID-19 outcomes between popu-
lations in general. Besides the economic and sanitary
conditions that make Latin American countries more vul-
nerable to the pandemic, the lack of unambiguous defini-
tions of COVID-19 cases and deaths and the limited
testing capacity represent major challenges for data quality
assessment.19–21 We focus here on definitions and testing
strategies.
With respect to COVID-19 case and death definitions,
criteria have varied since records started. At the time of
data retrieval, both countries use laboratory, clinical and
epidemiological criteria to confirm SARS-CoV-2 infec-
tions.22,23 However, the vast majority of COVID-19 cases
and deaths are confirmed with RT-PCR tests results in
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both populations (99.6% and 91.6% in Colombia and
Mexico, respectively).24,25 Regarding the definition of
tests, whereas in Colombia it refers to laboratory samples
tested (4.5 M as of 7 November 2020), in Mexico it alludes
to persons (2.3 M). Because individuals may be tested more
than once, comparison between these two units is not
straightforward. Testing performance measures, such as
positive rates (e.g. 30% in Colombia and 45% in
Mexico26), are essential for interpreting differences in cases
and deaths across populations, because they help to assess
the extent of infection under-reporting.27 However, differ-
ences in test definitions pose serious challenges for direct
comparisons. Dates in both sources are comparable, corre-
sponding to the occurrence of events. Since information
from both sources relies on individual-level databases,
delays in diagnosis and death registration are retrospec-
tively adjusted.
Differences in testing capacity and strategy between
countries are also key determinants for infection diagnosis.
Given both the magnitude of contagion and limited resour-
ces in the region, Latin American countries have struggled
to increase testing capacity proportionally to the spread of
the infection.28,29 Although with very limited capacity, the
testing approach of Colombia has been to test as many sus-
pected cases as possible. In contrast, an important part of
the test strategy in Mexico has focused on inferring the ex-
tent of contagion in the population by using nationally rep-
resentative samples (known as Centinela, which represent
36.5% of all confirmed infections at the date under obser-
vation), and it has gradually included a small proportion
of suspected infections outside the Centinela system.23
Figure 2 Relationship between deaths and cases per 100 000 population
by age group and sex in Colombia, until 7 November 2020. Diagonal
lines indicate the case fatality ratio.
Figure 1 Availability of national and subnational information on COVID-19 cases, deaths, and tests in the countries included in the database as of 7
January, 2021.
Figure 3 Relationship between deaths and cases per 100 000 population
by age group in Mexico and Colombia, until 7 November 2020.
Diagonal lines indicate the case fatality ratio.
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On 7 November 2020, Colombia performed five times
more tests per capita than Mexico. These differences in
testing regimes between both countries may account for a
substantial part of the CFR discrepancies observed in
Figure 3.
The differences in definitions and testing strategies be-
tween populations highlight challenges in making compari-
sons and also the need to produce data with sufficient
detail to adjust for biases. For this reason, alongside data
on cases, deaths and tests, COVerAGE-DB offers addi-
tional information on metadata and quality metrics that
are needed for a cautious interpretation of the data and
their limitations. It is our view that researchers should tri-
angulate creatively from all available data rather than
avoid difficult comparisons.
Strengths and weaknesses
Since the beginning of the pandemic, it has been evident that
population characteristics are key to understanding the
prevalence, spread and fatality of COVID-19 across coun-
tries. However, data on cases, deaths and tests disaggregated
by age and sex are not easily comparable across countries,
and sometimes not even accessible. The main strength of
COVerAGE-DB is to provide a centralized, open-access and
fully reproducible repository of age-and sex-specific case,
death and test counts from COVID-19, collected from offi-
cial sources and harmonized to standard output formats.
The data harmonization process is transparent, following a
strict protocol.2 The initial input data are provided
alongside the harmonized counts, as well as the code used to
harmonize the different input measures, metrics and age
groups into comparable granular output metrics. All scripts
are written in the open-source R programming language.30
The data sources and limitations are documented for each
country in a standard metadata framework.
A limitation of the COVerAGE-DB is the heterogeneous
and difficult-to-evaluate quality of the underlying data. No
single data source can currently claim accurate estimates of
COVID-19 incidence or fatalities. Age-specific case counts
are highly dependent upon the testing capacity,31 testing
strategy32 and differences in the definition of cases across
sources and over time. Recorded cases underestimate infec-
tions everywhere, with underestimation expected to vary by
age, given the relationship between age and case severity.33
The accuracy of diagnostic RT-PCR tests used to confirm
infections is also known to vary.34 Furthermore, at any
given date, cumulative counts are underestimated because of
the lag between infection and a positive test result.35
Death counts from COVID-19 are also likely underesti-
mated for similar reasons and also due to various kinds of
delays in death registration. Media reports have circulated
about intentional data manipulation in some of the official
data covered in the database.36 Excess all-cause mortality
has been observed across many regions.37–40 Although
some of these deaths likely are from postponing or forego-
ing treatment from non-COVID-19-related causes, the
magnitude of this excess is suggestive that numerous
COVID-19-related deaths are classified under different
causes. Populations also differ in whether deaths of
Figure 4 View of the Open Science Framework (OSF) repository, File section [https://osf.io/mpwjq/files/]. To download data files, click on Data, and se-
lect one of the files.
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suspected COVID-19 cases are included in official statistics
and in post-mortem practices when an infection is sus-
pected.41 Some populations only report deaths occurring in
hospitals, neglecting a potentially sizeable proportion of
deaths occurring in institutional settings and at home.42
Most populations currently report all deaths to confirmed
SARS-CoV-2 infections as COVID-19 deaths for this data-
base, but the underlying cause of death eventually reported
on the death certificate may differ in patients with severe
comorbidities. To mitigate biases and misinterpretations
due to different practices and definitions, such information
is constantly updated and documented in the metadata of
the database which are freely accessible to users. Further, a
supplementary data quality metrics file contains a suite of
data quality indicators that is easily merged with the main
output data. Quality metrics include age-reporting com-
pleteness, some indicators on how aggressive age harmoni-
zation is, and two positivity measures from Our World in
Data database on COVID-19 testing.26
All of these issues compromise the comparability of the
data contained within the COVerAGE-DB, both across pop-
ulations at any given time and within populations over time.
That is, the database enables direct calculation of age-
specific CFRs, but one must be careful when making com-
parisons. Care must also be taken not to interpret calculated
CFRs as infection fatality ratios, the latter of which include
both detected and undetected SARS-CoV-2 infections in the
denominator. Proper estimation of incidence and fatality,
and of total demographic impacts, will likely require triangu-
lating data across numerous sources as these become avail-
able. To this end, the COVerAGE-DB was designed to be
easily merged with other databases such as the Our World In
Data testing or excess mortality data,26 the COVID-19 dash-
board of Johns Hopkins,43 the World Population Prospects
database44 and the Short Term Mortality Fluctuations data-
base.40 Moreover, given that we have near-complete time se-
ries capturing the whole pandemic curve in some places,
careful modelling of lag structures might allow some of these
data-driven biases to be estimated.
Data resource access
Both merged input and harmonized output files can be
downloaded directly from the OSF site [https://osf.io/
mpwjq doi: 10.17605/OSF.IO/MPWJQ, which contains a
folder called ‘Data’ with four files of primary data.
Figure 4 shows where to find the files in the OSF
repository.
Each of the main data files has a stable link (see
Table 1) which always points to the most recent version.
Each file is a zipped csv file by the same name. For stable
links to download particular versions, click on the version
number in the Version column seen in Figure 4. Users can
note versions either by referring to timestamps provided in
the headers of data files or by referring to OSF file version
numbers, which increment with each daily update.
A data dictionary is given in both the OSF wiki [https://
osf.io/mpwjq/wiki/home/] and the Method Protocol.2 Files
are shared in csv format to be as universally accessible as
Table 1 The main data files, a description of their content,
and their stable URLs
Filename Description Stable URL
























Profile in a nutshell
• COVerAGE-DB is an open-access database including
cumulative counts of confirmed COVID-19 cases,
deaths and tests by age and sex. Original data and
sources are provided alongside data and measures
in age-harmonized formats.
• The database is in continuous development. It
includes data since January 2020, and as of 7
January 2021, it includes 108 countries and 371
subnational areas.
• The database also documents variations in definitions
of all input data and indicators of reporting
completeness across sources and over time.
• An international team, composed of more than 60
researchers, contributed to the collection of data and
metadata in COVerAGE-DB from governmental
institutions, as well as to the design and
implementation of the data processing and validation
pipeline. We encourage researchers interested in
supporting this project to send a message to the
email: [coverage-db@demogr.mpg.de].
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possible. A guide to getting started using the data in R is
also provided [https://bit.ly/3g8nIVU], to merge
COVerAGE-DB with other databases, and tips for other
statistical packages may also be added. Users are encour-
aged to reach out for further information or advice on us-
ing the database, or to express interest in the project at:
[coverage-db@demogr.mpg.de].
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19 no Brasil: quantos e quais estamos identificando? [Deaths due
to COVID-19 in Brazil: how many are there and which are being
identified?] Rev Bras Epidemiol 2020;23. doi:
10.1590/1980-549720200053.
20. Rao C. Bulletin of the World Health Organization. Medical
Certification of Cause of Death for COVID-19. 2020. http://www.
who.int/bulletin/volumes/98/5/20-257600/en/ (10 November
2020, date last accessed).
21. Pe~na R. Y al Tercer Dı́a, Resucitó [And on the third day, he resus-
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